Atara Biotherapeutics EVP Global Head of R&D Jakob Dupont resigns, enters consulting agreement

Atara Biotherapeutics, Inc.

Dr. Jakob Dupont, EVP Global Head of R&D, resigned effective May 12, 2023.
Entered consulting agreement through Dec 31, 2023; monthly fees $15,000 through Aug 31 then $4,500, plus $300/hr excess.
Outstanding equity awards will continue to vest during the consulting term.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jakob Dupont

Executive Vice President, Global Head of Research and Development

ATRA · Atara Biotherapeutics, Inc.

Effective: 2023-05-12
Filed: May 12, 2023, 7:59 PM ET

On May 12, 2023, Dr. Dupont resigned from the Company and entered into a consulting agreement with the Company, pursuant to which Dr. Dupont will provide consulting services to the Company through December 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jakob Dupont resigned as Executive Vice President, Global Head of Research and Development at Atara Biotherapeutics, Inc..

Action: resigned
Role: Executive Vice President, Global Head of Research and Development

Exact text from the filing

On May 12, 2023, Dr. Dupont resigned from the Company and entered into a consulting agreement with the Company, pursuant to which Dr. Dupont will provide consulting services to the Company through December 31, 2023.

View on SEC.gov

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021809

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.